1. CAPTURE: C 7E3 Fab A nti- P latelet T herapy in U nstable RE fractory Angina ¤ Study Population:Patients with chest pain at rest and ECG signs of UA (NQMI excluded) proven refractory to 2-48 hours of heparin and nitroglycerin and determined eligible via diagnostic catheterization for PCI within 18-24 hours ¤ Dosing arms:ASA + standard-dose, weight-adjusted heparin - abciximab 0.25 mg/kg bolus + 10 µg/min infusion for 18-24 hours pre-PCI and 1 hour post-PCI (n=630) - placebo (n=635) ¤ Primary endpoint:Death, MI, or urgent repeat intervention at 30 days The CAPTURE Investigators. Lancet. 1997; 349: 1429-1435.

2. CAPTURE Study design heparin + nitroglycerin Diagnosis of UA Chest pain with ECG signs of ischemia (non-Q-wave MI excluded) 2 - 48 hours ASA + heparin + abciximab Diagnosis of refractory UA Chest pain with ECG signs of ischemia with heparin + nitroglycerin Diagnostic catheterization confirming eligibility for PCI PCI 18 - 24 hours pre-PCI 1 hour post-PCI The CAPTURE Investigators. Lancet. 1997; 349: 1429-1435.

3. CAPTURE Efficacy results summary Endpoint Death, MI, or urgent repeat intervention Death, MI, or any revascularization Death MI Urgent repeat intervention Any revascularization Time 30 days 6 months 30 days 6 months Pre-PCI 30 days 6 months 30 days 6 months Placebo (n=635) 15.9% 30.8% 1.3% 2.2% 2.1% 8.2% 9.3% 10.9% 24.9% Abciximab (n=630) 11.3% 31.0% 1.0% 2.8% 0.6% 4.1% 6.6% 7.8% 25.4% P value vs placebo 0.012 ns ns ns 0.029 0.002 nsns The CAPTURE Investigators. Lancet. 1997; 349: 1429-1435.

4. Safety endpoint Major TIMI bleeding Minor TIMI bleeding Platelet count < 100,000/mm 3 Placebo (n=635) 1.9% 2.0% 1.3% Abciximab (n=630) 3.8% 4.8% 5.6% CAPTURE Safety results summary The CAPTURE Investigators. Lancet. 1997; 349: 1429-1435.